Centessa Pharmaceuticals Prices Upsized $225M Public Offering of ADS

BOSTON and LONDON, Sept. 12, 2024 - Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, has announced the pricing for an expanded underwritten public offering. This offering includes 15,254,237 American Depositary Shares (ADSs), with each ADS representing one ordinary share. The public pricing is set at $14.75 per ADS. The total gross proceeds from this offering are projected to be nearly $225 million, prior to deducting underwriting discounts, commissions, and other expenses. Centessa is the sole seller of the ADSs in this transaction.

The transaction is anticipated to close around September 16, 2024, dependent on the fulfillment of standard closing conditions. Additionally, Centessa has given underwriters a 30-day option to buy up to an extra 2,288,135 ADSs at the set public offering price, minus underwriting discounts and commissions.

Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets are leading the management of the offering.

The ADSs are being offered based on a registration statement on Form S-3, filed with the Securities and Exchange Commission (SEC) on September 11, 2024, which became effective immediately upon filing. Preliminary and final prospectus supplements, along with the accompanying prospectus for the offering, will be filed with the SEC and can be accessed on their website.

This communication is not an offer to sell these securities nor a solicitation to buy them in any area where such activities would be illegal before registration or qualification under the relevant securities laws.

Centessa Pharmaceuticals is a clinical-stage company focused on discovering and developing transformative medicines for patients. Their leading programs include a hemophilia treatment, an orexin agonist program for narcolepsy and other sleep disorders, and an immuno-oncology initiative based on their LockBody® technology platform. The company believes that each of their programs has the potential to revolutionize current treatment standards and establish new benchmarks in care.